Phil Dundee is a urologist with specialist expertise in robotic and laparoscopic surgery. After completing his general urology training in Melbourne, he undertook fellowship training in laparoscopic surgery at The Royal Surrey County Hospital, followed by a year of robotic training at Guy’s and St Thomas’ Hospital. Since returning to Melbourne at the end of 2012, Phil has established the first robotic cystectomy surgery program in Melbourne and leads the Robotic Surgery Fellowship program at The Royal Melbourne Hospital. He has been an invited speaker and faculty member at national and international robotic surgery workshops and received the Peter J Dohrmann medal from the Epworth Hospital in 2018 for research in robotic surgery.

David F. Penson, MD, MPH is the Hamilton and Howd Chair in Urologic Oncology, Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair, Department of Urology at Vanderbilt University Medical Center. He obtained his MD from Boston University and completed his urology residency at UCLA Medical Center in Los Angeles. He then was awarded a Robert Wood Johnson Clinical Scholar fellowship at Yale University and also obtained an MPH at Yale. He currently maintains a clinical practice in urologic oncology at the Vanderbilt-Ingram Cancer Center. His specific research interests include the comparative effectiveness of treatment options in localized prostate cancer and the impact of the disease and its treatment on patients’ quality of life. He has received federal grant funding from the National Cancer Institute, the US Agency for Healthcare Research and Quality, the Centers for Disease Control and Prevention and the Patient-Centered Outcomes Research Institute. His work has been published in various high-profile journals, including the New England Journal of Medicine, JAMA and the Annals of Internal Medicine. He previously chaired the National Institutes of Health’s Health Services Outcomes and Delivery (HSOD) study section, which reviews almost all health services research grant submitted to the NIH. He also maintains a strong interest in health policy and quality improvement. He currently serves as the Secretary of the American Urological Association.

Dr. Reiter is the Bing Professor of Urologic Oncology and Chief of the Division of Urologic Oncology. He attended Stanford Medical School, completed his urologic training at Stanford and Baylor College of Medicine, and completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute. Dr. Reiter is an internationally recognized expert in all areas of prostate cancer management and research. He was among the first to integrate functional MRI imaging and PSMA PET imaging into the diagnosis, surgical management, and care of men with prostate cancer. He was also an early innovator in the field of robotic surgery, and has completed more than 2,500 robotic prostatectomies. In addition to surgical management of prostate cancer, Dr. Reiter has expertise in MRI-guided biopsies to diagnose prostate cancer, focal therapy to treat select individuals, as well as all forms of medical therapy. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans in collaboration with UCLA leaders in the areas of radiation, medical and nuclear prostate oncology. In addition to his broad clinical interests in prostate cancer, Dr. Reiter is a leading researcher in prostate cancer and has led UCLA’s 12 million SPORE grant, which supports work to translate laboratory discoveries into clinical advances, for more than 15 years. Drugs such as enzalutamide and apalutamide, and imaging tools such as PSMA PET, are among the many advances that have emanated from this program. His own laboratory discovered the prostate stem cell antigen and developed antibodies to target this protein, which has led to novel imaging and therapeutic approaches for prostate cancer currently in clinical trials. Dr. Reiter has authored more than 250 papers and lectures nationally and internationally on all aspects of clinical care of men with prostate cancer.

Kindly sponsored by


Dr. Matthew is a Health and Clinical Psychologist as well as a Clinician-Investigator in the Department of Surgery, Division of Urology, and an Associate Professor in both the Departments of Surgery and Psychiatry at the University of Toronto. He serves as the Lead Psychologist, Director of the Sexual Health Program, Director of Psychology Training, and Head of the GU Survivorship Program at Princess Margaret Cancer Centre in Toronto, Canada. With over 150 published scientific articles, reviews, and chapters in cancer survivorship, Dr. Matthew has been instrumental in shaping national and international guidelines for sexual healthcare in cancer (ASCO/CCO, Movember). His clinical care and research are centered on urologic cancers, focusing on prevention, sexual health, survivorship, and improving patient quality of life.

Dr. Arvin George is a urologic surgeon specializing in the diagnosis and management of genitourinary cancers. He currently serves as an Associate Professor of Urology and Director of Prostate Cancer Programs at the Johns Hopkins School of Medicine. After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his Urology Residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He also completed his Endourology fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a Urologic Oncology fellowship at the National Cancer Institute, National Institutes of Health. Dr. George’s clinical practice includes both surgical and non-operative management of prostate, kidney, and upper tract urothelial cancers. His research interests include minimally invasive and image-guided treatments, functional prostate imaging and focal therapy for prostate cancer.

Peter is a Urologic Surgeon with a special interest in Cancer of the Prostate, and Medico-Legal practice. Having completed Urology Speciality training in Queensland Peter spent further time in Cardiff, United Kingdom and in Toronto, Canada developing Reconstructive and Radical Prostatectomy skills. Peter is an Adjunct Professor at the Australian Prostate Cancer Research facility at QUT/PAH and Adjunct Clinical Professor Monash University Dept of Epidemiology. He is Co-chair of the Steering Committee of the Review of the Guidelines for the Early detection of Prostate Cancer in Australia. Current appointments include Member of External Panel of Experts in Urology - Avant Medical Insurance, Panel Member Professional Services Review Australian Government, Medical Board of Australia performance assessor. He is a member of the Board of Directors of the Prostate Cancer Foundation Australia and Australasian Urological Foundation. He was elected a Fellow of the Urological Society of Australia and New Zealand in 2024 having served as President and on the board of directors.